List of Excipients in Branded Drug PATANASE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Alcon Laboratories Inc	PATANASE	olopatadine hydrochloride	0065-0332	BENZALKONIUM CHLORIDE
Alcon Laboratories Inc	PATANASE	olopatadine hydrochloride	0065-0332	EDETATE DISODIUM
Alcon Laboratories Inc	PATANASE	olopatadine hydrochloride	0065-0332	HYDROCHLORIC ACID
Alcon Laboratories Inc	PATANASE	olopatadine hydrochloride	0065-0332	SODIUM CHLORIDE
Alcon Laboratories Inc	PATANASE	olopatadine hydrochloride	0065-0332	SODIUM HYDROXIDE

Patanase Excipient Strategy and Commercial Opportunities for Olopatadine Nasal Spray

Last updated: September 13, 2026

Patanase is an aqueous nasal spray containing olopatadine hydrochloride, an intranasal H1 antihistamine. Its formulation uses a conventional buffered, isotonic, multidose system with benzalkonium chloride as preservative. The main commercial opportunities are generic substitution, preservative-free delivery, improved spray devices, pediatric formats, combination products, and lifecycle extensions built around tolerability and adherence rather than new olopatadine chemistry.

What is Patanase and how is it formulated?

Patanase nasal spray contains 0.6% olopatadine hydrochloride and delivers 665 micrograms of olopatadine per spray. The product is indicated for seasonal allergic rhinitis and is administered intranasally twice daily.[1]

Patanase formulation composition

Component	Function in formulation	Commercial relevance
Olopatadine hydrochloride	Active antihistamine	Soluble salt form suitable for aqueous delivery
Benzalkonium chloride	Antimicrobial preservative	Supports multidose packaging but can create tolerability and differentiation issues
Dibasic sodium phosphate	Buffering agent	Maintains pH and supports chemical stability
Sodium chloride	Tonicity modifier	Reduces nasal discomfort from hypotonic or hypertonic solutions
Edetate disodium	Chelating agent	Helps control metal-catalyzed degradation and supports preservative performance
Hydrochloric acid and/or sodium hydroxide	pH adjustment	Controls product pH
Purified water	Vehicle	Provides a low-cost, scalable nasal-spray matrix

The labeled formulation has an acidic pH of approximately 3.7. Each bottle contains approximately 240 metered sprays, which supports a 30-day adult treatment period at two sprays per nostril twice daily.[1]

What role does each excipient play?

The formulation is designed around four technical requirements:

1. Maintain olopatadine solubility in an aqueous vehicle.
2. Preserve microbiological quality during repeated use.
3. Deliver a reproducible spray volume and plume.
4. Minimize nasal irritation while maintaining chemical and physical stability.

Olopatadine hydrochloride is materially easier to formulate as a solution than as a suspension. A solution avoids sedimentation, shaking requirements, and dose variability associated with suspension products. The principal formulation risk is therefore not active-drug dissolution but control of pH, preservative concentration, container compatibility, and spray performance.

What excipient strategy does Patanase use?

Patanase uses a conventional multidose preserved aqueous strategy. Benzalkonium chloride is the central commercial and technical excipient issue.

Why benzalkonium chloride matters

Benzalkonium chloride is effective at low concentration and is widely used in multidose nasal products. It allows a pump bottle to be used repeatedly without unit-dose packaging. That reduces packaging cost and improves manufacturing simplicity.

The tradeoff is potential local tolerability. Repeated exposure to benzalkonium chloride has been associated with concerns about nasal irritation and mucosal effects, particularly in chronic-use products. The regulatory issue is product-specific, but preservative burden is a recognized differentiation point in nasal drug delivery.

A competing product can therefore pursue a preservative-free position by using:

• Unit-dose ampoules.
• A sterile metered-dose pump with a validated microbial barrier.
• A one-way valve system.
• A multidose bottle with a validated preservative-free closure and pump.
• A packaging system that limits backflow and contamination.

A preservative-free product would require more demanding container-closure validation and microbiological challenge data. The higher packaging cost could be justified in pediatric, chronic-use, premium allergy, or specialist channels.

Buffer and tonicity optimization

The phosphate buffer and sodium chloride system is commercially attractive because it is inexpensive, familiar to regulators, and compatible with high-volume aqueous manufacturing. A reformulator could investigate:

• Lower buffer capacity to reduce irritation.
• Alternative buffers such as citrate or histidine.
• Adjusted sodium chloride concentration to improve nasal comfort.
• Near-physiological tonicity.
• Reduced ionic strength to improve compatibility with pump materials.
• pH optimization around olopatadine stability, solubility, and tolerability.

Any change must be evaluated against spray performance, preservative efficacy, impurity growth, pH drift, and device compatibility. A lower-pH product may improve chemical stability but can increase stinging. A more physiologic product may improve patient acceptance but create a narrower stability or preservative window.

What formulations are protected by Patanase-related patents?

Patanase’s original intellectual-property position centered on olopatadine formulations and intranasal delivery rather than a complex biologic or device-dependent product. The core product is now exposed to generic competition, and the principal commercial barriers are manufacturing validation, device performance, regulatory execution, and market access.

Patent and exclusivity position

Issue	Patanase assessment
Active ingredient	Olopatadine hydrochloride is an established small molecule
Dosage form	Aqueous metered nasal spray
FDA pathway	Abbreviated New Drug Application is the principal generic route
Original NDA	FDA-approved Patanase nasal spray NDA
Regulatory exclusivity	Original approval exclusivity has expired
Core formulation patents	Original patent protection has matured or is no longer the main barrier to entry
Orange Book relevance	Current listed patents and regulatory exclusivity must be checked against the live FDA Orange Book record
Biosimilar exposure	None; olopatadine is a chemically synthesized small molecule, not a biologic
Current litigation risk	More likely to involve ANDA certification, labeling, device equivalence, or commercial launch than biologic patent disputes

The key legal point is that a generic applicant can generally pursue an ANDA for olopatadine nasal spray if it can demonstrate pharmaceutical equivalence, bioequivalence where required, equivalent labeling, and acceptable device performance. Paragraph IV risk is substantially lower once core listed patents have expired, but a new applicant must still assess any live Orange Book listings, pediatric extensions, formulation patents, and method-of-use claims.

When does Patanase lose exclusivity and what does generic entry look like?

Patanase has already moved beyond its original branded exclusivity period. Generic olopatadine nasal sprays have entered the U.S. market, making substitution and payer contracting the principal competitive factors.

Generic launch scenarios

Scenario	Likely commercial effect
Standard preserved generic	Lowest-cost entry; direct substitution against Patanase
Authorized or branded generic	Maintains brand-like positioning while reducing price
Preservative-free generic	Premium differentiation and potential use in sensitive patients
Device-focused generic	Competes on plume, actuation force, priming, and dose consistency
Pediatric-oriented product	Targets caregiver acceptance and ease of administration
Combination nasal spray	Higher development burden but potentially stronger clinical differentiation
OTC-oriented extension	Requires a separate FDA regulatory and labeling strategy

A standard generic has the shortest development path but faces intense price competition. A preservative-free or device-optimized product may achieve better gross margins, although it would require comparative performance data and more complex packaging.

What is the Orange Book status of Patanase?

The Orange Book remains the controlling source for current U.S. patent listings, approval status, and therapeutic-equivalence information.[2] Patanase should be assessed through three separate categories:

1. Listed patents attached to the reference product.
2. Regulatory exclusivity attached to the reference product.
3. Therapeutic-equivalence codes assigned to approved generic products.

A patent listing does not by itself establish that a patent will block market entry. The relevant questions are whether the patent remains unexpired, whether it is listed for the reference product, whether the proposed generic product infringes the claims, and whether the applicant files a Paragraph IV certification or another certification permitted under the ANDA rules.

Which companies are challenging Patanase?

Generic olopatadine nasal spray has been commercially developed by multiple generic manufacturers. The relevant competitive set typically includes large multisource suppliers and companies with established nasal-device manufacturing capabilities. Company-level market share changes over time because of supply contracts, wholesaler relationships, shortages, and pharmacy benefit formulary decisions.

The strongest challengers are companies that can combine:

• FDA-approved nasal-device platforms.
• High-volume sterile or controlled aqueous manufacturing.
• Reliable preservative and microbial-control systems.
• Low-cost packaging procurement.
• Payer and retail pharmacy access.
• Capacity to support both 30-day and institutional demand.

The competitive market is therefore not determined by active-ingredient access alone. Pump assembly, filling precision, container-closure integrity, and supply reliability can determine whether an approved generic achieves meaningful substitution.

How strong is the Patanase patent estate?

The current patent estate is commercially weak as a barrier to ordinary generic entry because the product is an established small-molecule nasal spray with expired original exclusivity and available generic competition.

Remaining areas with possible strategic value

Patent value could still arise in narrower claims directed to:

• Preservative-free multidose delivery.
• Specific pump and valve architectures.
• Reduced actuation force.
• Improved plume geometry.
• Low-drip or low-runoff delivery.
• Stability under temperature excursions.
• Specific pH and buffer combinations.
• Combination products containing olopatadine and another active ingredient.
• New dosing regimens or patient populations.
• Manufacturing processes that reduce impurities or improve sterility assurance.

These claims would need to be drafted around a genuine technical advantage. Broad claims covering olopatadine in a conventional aqueous nasal spray would face substantial validity and obviousness pressure.

What commercial opportunities exist for Patanase excipient reformulation?

1. Preservative-free olopatadine nasal spray

This is the clearest excipient-led opportunity. A preservative-free formulation could target patients who experience nasal irritation or who require extended seasonal use. The main development challenge is microbial protection after opening.

The product would need:

• A validated multidose microbial-barrier system or unit-dose package.
• Container-closure integrity data.
• In-use stability data.
• Microbial challenge testing.
• Demonstrated dose uniformity through the labeled in-use period.
• Evidence that the new system does not change plume geometry or delivered dose.

2. Improved tolerability formulation

A reformulator could reduce perceived stinging by optimizing pH, buffer capacity, ionic strength, and excipient concentration. The commercial claim would need to be supported by human tolerability data rather than formulation theory alone.

Potential positioning includes:

• "Gentle" nasal delivery.
• Pediatric-friendly administration.
• Reduced post-dose irritation.
• Better suitability for repeated seasonal use.

3. Advanced nasal-device platform

The device may offer more commercial leverage than the excipients. A new pump could improve:

• Dose uniformity at the beginning and end of bottle life.
• Performance after storage.
• Priming and repriming behavior.
• Spray angle and plume width.
• Ease of actuation.
• Reduced dripping into the throat.
• Delivery consistency across users.

Device claims can also create a more defensible intellectual-property position than conventional excipient substitutions.

4. Pediatric presentation

The approved label includes use in children six years and older, with a lower spray count than the adult regimen.[1] A pediatric-focused product could use a smaller bottle, a shorter nozzle, a lower-actuation-force pump, or packaging designed for caregiver administration.

The excipient strategy should prioritize low irritation, low taste impact from runoff, and reliable metering at low actuation force.

5. Combination products

Olopatadine could be combined with an intranasal corticosteroid or another allergy active ingredient. Combination products can offer greater symptom coverage but face higher regulatory and clinical-development requirements.

The formulation risks include:

• Chemical interaction between active ingredients.
• Different optimal pH ranges.
• Preservative compatibility.
• Increased total drug load.
• More complex spray-device requirements.
• Greater labeling and clinical-efficacy burden.

A combination product is more likely to support premium pricing than a standard olopatadine generic, but it is also more exposed to clinical and regulatory execution risk.

How does Patanase compare with competing allergy nasal sprays?

Attribute	Patanase	Intranasal corticosteroid	Azelastine nasal spray
Drug class	H1 antihistamine	Corticosteroid	H1 antihistamine
Main benefit	Rapid allergy symptom relief	Broad anti-inflammatory control	Rapid antihistamine activity
Formulation	Aqueous solution	Often suspension or solution	Typically aqueous solution
Excipient priority	Preservative, buffer, tonicity, spray delivery	Suspension stability or solution stability	Preservative and taste control
Commercial differentiation	Preservative-free, device, tolerability	Efficacy, once-daily dosing, combination products	Onset, taste, device, combination therapy
Generic pressure	High	High	High
Biosimilar risk	None	None for small molecules	None

Patanase competes in a crowded generic market. The product is less attractive as an undifferentiated low-cost generic than as a platform for preservative-free delivery, improved tolerability, or combination therapy.

What manufacturing and IP barriers affect commercialization?

The manufacturing process is relatively accessible compared with biologic or sterile injectable products, but nasal sprays require tight control over both formulation and device.

Important barriers include:

• Uniform dissolution of olopatadine hydrochloride.
• Control of pH and osmolality.
• Preservative efficacy.
• Low bioburden during filling.
• Pump-to-pump dose reproducibility.
• Container-closure integrity.
• Extractables and leachables from the pump and bottle.
• Spray-pattern consistency.
• In-use stability after repeated actuation.
• Supply continuity for pump components.

A formulation that is chemically stable in a glass laboratory vessel may perform differently in a plastic commercial bottle with elastomeric components. Device compatibility and extractables testing should therefore be integrated early in development.

What litigation and Paragraph IV risks affect Patanase?

The principal litigation risk for a new olopatadine nasal-spray applicant would arise from any still-listed patent covering formulation, device, method of use, or a specific combination product. A Paragraph IV certification could trigger patent litigation and a potential 30-month stay under the Hatch-Waxman framework if statutory conditions are met.[3]

For a conventional olopatadine nasal spray, the more material risks are likely to be:

• Failure to demonstrate equivalent device performance.
• Labeling differences.
• Inadequate in-use stability.
• Formulation-related deficiencies.
• Patent claims directed to a modified delivery system.
• Commercial supply interruptions after approval.

Biosimilar litigation is not relevant because olopatadine is a small-molecule drug. The applicable regulatory route is ANDA approval, not an abbreviated biologics license application.

What is the revenue exposure and commercial value?

Patanase’s branded revenue exposure is constrained by generic competition and the availability of lower-cost substitutes. The larger opportunity lies in market segmentation rather than preservation of the original branded position.

Commercial attractiveness by strategy

Strategy	Development burden	Margin potential	Differentiation
Standard generic	Low to moderate	Low	Low
Preservative-free product	Moderate to high	Moderate to high	High
Pediatric device	Moderate	Moderate	Moderate
Premium pump	Moderate	Moderate	Moderate to high
Combination product	High	High	High
OTC conversion	High	Potentially high	High

A company seeking rapid entry would favor a conventional ANDA. A company seeking defensible pricing would favor preservative-free packaging, a differentiated device, or a combination product supported by clinical evidence.

Key Takeaways

• Patanase is a 0.6% olopatadine hydrochloride aqueous nasal spray delivering 665 micrograms per actuation.
• Its excipient system uses benzalkonium chloride, phosphate buffer, sodium chloride, edetate disodium, pH adjusters, and purified water.
• The original product is exposed to generic competition, and biosimilar risk does not apply.
• The strongest formulation opportunity is a preservative-free multidose or unit-dose product.
• Device performance, nasal tolerability, and pediatric usability offer more commercial differentiation than conventional excipient substitution.
• A standard generic has the lowest development burden but faces severe price competition.
• Combination products and OTC-oriented strategies have higher commercial upside but require more substantial regulatory and clinical work.
• Current patent and Orange Book positions should be evaluated against the live FDA records before launch or licensing decisions.

FAQs

Is Patanase preservative-free?

No. The labeled Patanase formulation contains benzalkonium chloride as a preservative.[1]

Can olopatadine nasal spray be reformulated without benzalkonium chloride?

Yes, but the product would require an alternative microbial-control strategy, such as unit-dose packaging or a validated preservative-free multidose delivery system.

Is Patanase a biologic requiring biosimilar competition analysis?

No. Olopatadine hydrochloride is a chemically synthesized small molecule. Generic competition proceeds through the ANDA pathway.

What is the most valuable patent opportunity for an olopatadine nasal spray?

A patent covering a technically demonstrated preservative-free multidose system, superior spray delivery, or a clinically meaningful combination product is likely to be more valuable than a broad claim covering conventional olopatadine solution formulations.

Does a new excipient automatically create a new exclusivity period?

No. Excipient changes do not independently create regulatory exclusivity. Any exclusivity would depend on the regulatory pathway, new clinical data, formulation or device innovation, and applicable FDA rules.

References

1. U.S. Food and Drug Administration. (2008). Patanase nasal spray: Prescribing information.
2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book.
3. U.S. Food and Drug Administration. (2017). ANDA submissions: Content, format, and review of abbreviated new drug applications.
4. U.S. Food and Drug Administration. (2024). Inactive ingredient database.